Tryg A/S
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme
On 04 December 2024, Tryg A/S (“Tryg”) announced that the Board of Directors had decided to initiate a share buyback programme of up to DKK 2.0 billion. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 30 June 2025.
Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.
The following transactions have been executed in the period 22 April 2025 to 25 April 2025:
| | Number of shares | Avg. purchase price, DKK | Transaction value, DKK |
| 22 April 2025 | 90,000 | 152.88 | 13,759,200 |
| 23 April 2025 | 70,000 | 153.23 | 10,726,100 |
| 24 April 2025 | 70,000 | 154.41 | 10,808,700 |
| 25 April 2025 | 75,000 | 152.46 | 11,434,500 |
| Accumulated for the period | 305,000 | | 46,728,500 |
| Accumulated under the programme | 10,581,787 | | 1,614,800,834 |
Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.
Following the above transactions, Tryg owns a total of 11,008,309 treasury shares corresponding to 1.786% of the total share capital.
Contact information:
- Gianandrea Roberti, Head of Financial Reporting, SVP +45 20 18 82 67, gianandrea.roberti@tryg.dk
- Robin Hjelgaard Løfgren, Head of Investor Relations, +45 41 86 25 88, robin.loefgren@tryg.dk
- Peter Brondt, Investor Relations Director +45 22 75 89 04, peter.brondt@tryg.dk
Visit tryg.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Junshi Biosciences7.9.2025 14:30:00 CEST | Press release
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
KOORUI7.9.2025 06:24:16 CEST | Press release
HKC Group Enters Europe at IFA 2025 with Three Brands and Three World Premieres
Northland Power Inc.5.9.2025 23:59:34 CEST | Press release
Northland Power Announces Retirement of John Brace and Appointment of Sébastien Clerc to Its Board of Directors
DBV Technologies S.A.5.9.2025 22:30:00 CEST | Press release
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Vaisala Group5.9.2025 17:30:00 CEST | Press release
Vaisala Corporation: Share Repurchase 5.9.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom